- 83% intracranial objective response rate (iORR) with Bria-IMT™ in heavily pretreated advanced breast cancer patients with CNS metastases
- Median progression free survival (PFS) of 4.1 months in ADC resistant patients - double the PFS of patients in similar studies1,2,3
- Clinical benefit rate of 55% in evaluable patients includes HR+, HER2+ and TNBC disease - much higher than comparable studies1,2,3
“Patients with heavily pretreated metastatic breast cancer that have developed resistance to antibody drug conjugates (ADC) face a very poor prognosis. Novel, well tolerated and effective treatments remain a critical need,” stated
“Bria-IMT™ is a novel therapeutic which has the potential to address a major therapeutic challenge in the management of progressive metastatic breast cancer, and these early results with preliminary activity in a refractory patient setting are encouraging,” stated
“With 4 published abstracts and an oral presentation, we expect this year’s ASCO Annual Meeting to be a very important event for BriaCell,” stated
Oral presentation by Mayo Clinic Professor and Phase 2 Principal Investigator,
Abstract Number for Publication: 1022
Title: Outcomes of advanced/metastatic breast cancer (aMBC) treated with Bria-IMT™, an allogeneic whole cell immunotherapy.
Session Type and Title: Rapid Oral Abstract – Breast Cancer – Metastatic
Phase 2 clinical data of the Bria-IMT™ regimen in 54 advanced metastatic breast cancer patients who failed multiple prior treatments including ADCs and immune check point inhibitors (CPIs) (median of 6 prior treatments) are presented.
Clinical Efficacy
- Median progression free survival (PFS)# of 4.1 months in heavily pretreated ADC resistant patients
- PFS of 3.9 months in patients treated with planned pivotal Phase 3 formulation is double the PFS of patients in similar studies who received physician’s treatment of choice (the comparator in the ongoing phase 3 study)
- Overall response rate (ORR)## of 9.5% and clinical benefit rate (CBR)### of 55% in evaluable patients compares favorably with the literature (Table 1)
- 5/6 (83%) of evaluable patients (one inevaluable) with intracranial lesions treated with Bria-IMT™ in all BriaCell studies had intracranial responses, including complete and partial responses
# PFS is defined as the length of time during which a patient’s cancer does not get worse
## ORR defined as the percentage of patients who achieved either a complete response (complete disappearance of tumor) or partial response (tumor volume reduction of 30% or more)
### CBR defined as percentage of patients whose disease shrinks or remains stable over a certain time period
Table 1: Bria-IMT™ and historical clinical data in aMBC patients who failed multiple prior treatments | |||
Study | PFS (months) | ORR (%) | CBR (%) |
BriaCell’s Phase 2 patients who received pivotal Phase 3 study formulation (Bria-IMT™ regimen) | 3.9 | 9.5* | 55* |
BriaCell’s ADC Resistant Phase 2 patients who received pivotal Phase 3 study formulation (Bria-IMT™ regimen) | 4.1 | 12** | 53** |
Bardia, A. et. al. 1 | 1.7 | 4 | 8 |
Tripathy D. et. al. 2 | 1.9 | 3 | 10 |
O’Shaughnessy J. et. al. non-TNBC 3 | 2.3 | 4 | 7 |
O’Shaughnessy J. et. al. TNBC 3 | 1.6 | 5 | 10 |
*Data is for evaluable patients, n=42 with 12 not evaluable. | |||
** Data is for evaluable patients, n = 17 with 6 not evaluable. | |||
1,2,3 Data is shown for the intent to treat population for the control group treated with treatment of physician’s choice, which is the comparator in the BriaCell’s ongoing pivotal Phase 3 study. | |||
2 This paper describes patients with brain metastases. | |||
Safety profile
Therapy was well-tolerated with no Bria-IMT™ related discontinuations. Absence of both interstitial lung disease (ILD), a common serious adverse event with ADCs, and Bria-IMT™-related treatment discontinuations underscore Bria-IMT™’s excellent tolerability and favorable safety profile.
In conclusion, improved progression-free survival and clinical benefit, along with an excellent safety profile, were observed in heavily pre-treated advanced breast cancer patients versus literature reported data in other similar studies. BriaCell will continue to monitor these clinical responses in its current pivotal Phase 3 study of Bria-IMT™ and CPI in advanced metastatic breast cancer.
Poster presentations on
Following the presentations, copies of the presentations will be posted on https://briacell.com/scientific-publications/.
References
- Bardia A, et al. Final Results From the Randomized Phase III ASCENT Clinical Trial in
Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. J Clin Oncol. 2024 May 20;42(15):1738-1744. doi: 10.1200/JCO.23.01409. Epub 2024 Feb 29. PMID: 38422473. - Tripathy D, et al. Treatment with etirinotecan pegol for patients with metastatic breast cancer and brain metastases: final results from the phase 3 ATTAIN randomized clinical trial. JAMA Oncol. 2022;8(7):1047-1052. doi:10.1001/jamaoncol.2022.0514.
- O’Shaughnessy J et al. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2022 Sep;195(2):127-139. doi: 10.1007/s10549-022-06602-7. Epub 2022 May 11. PMID: 35545724; PMCID: PMC9374646.
About
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.
Safe Harbor
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about Dr. Saranya Chumsri’s delivery of an oral presentation outlining BriaCell’s positive clinical data of its lead product candidate, Bria-IMT™; BriaCell presenting two poster sessions and one abstract on the updated clinical data of BriaCell’s randomized Phase 2 study evaluating Bria-IMT™ in patients with advanced metastatic breast cancers at the 2024 ASCO; BriaCell’s collaboration with authors and BriaCell medical advisory board members
Neither the
Contact Information
Company Contact:
President & CEO
1-888-485-6340
info@briacell.com
Media Relations:
CORE IR
julesa@coreir.com
Investor Relations Contact:
CORE IR
investors@briacell.com
![](https://ml.globenewswire.com/media/NDgzNzhjYTctYjJiZi00MTlhLWI5ZmItZDBjYTdjOGFiMGE0LTExMDIyMjk=/tiny/BriaCell-Therapeutics-Corp-.png)
2024 GlobeNewswire, Inc., source